Curis, Inc.
CRISAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Aug 17, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jul 24, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 31, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 1, 2024 |
| Truist Securities | maintain | Buy | May 15, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 15, 2024 |
| HC Wainwright& Co. | maintain | Buy | May 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Feb 9, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 29, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 28, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 25, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 24, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Sep 7, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Sep 6, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 4, 2023 |
| HC Wainwright & Co. | maintain | Buy | Aug 3, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Jul 11, 2023 |
| Cantor Fitzgerald | maintain | Overweight | Jul 10, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jul 7, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jul 6, 2023 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-2.01| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 14, 2026 | $-4.02 | $-6.95 | — | $1.0M |
| May 12, 2026 | $-25.00 | $-5.80 | — | $1.7M |
| Mar 19, 2026 | $24.60 | $-8.72 | $1.1M | $3.2M |
| Nov 6, 2025 | $-9.80 | $-12.40 | $3.2M | $2.9M |
| Aug 5, 2025 | $-13.60 | $-39.80 | $2.7M | $2.6M |
| May 6, 2025 | $-25.00 | $-22.80 | $2.4M | $2.7M |
| Mar 31, 2025 | $-25.00 | $-27.20 | $3.3M | $2.2M |
| Nov 14, 2024 | $-34.00 | $-36.60 | $2.9M | $2.3M |
News
LEXINGTON, Mass., Nov. 5, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that the Company will report its third quarter 2026 financial and operating results on Thursday, November 12, 2026, at 4:00 p.m.
LEXINGTON, Mass., Oct. 16, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS) ("Curis" or the "Company"), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced that it has entered into securities purchase agreements with certain existing healthcare focused institutional investors for the purchase and sale of 16,666,680 shares of common stock (or pre-funded warrants to purchase shares of common stock…
LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced the pricing of its public offering with certain new and existing healthcare-focused institutional investors for the purchase and sale of 3,733,334 shares of common stock of the Company (or pre-funded warrants to purchase shares of common stock in lieu thereof) and warr…